Drug Trial Radar · NCT06122714
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Nov 7, 2023
Primary completion
Dec 4, 2024
Study completion Dec 4, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Nov 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4144 administered orally in healthy participants.
Conditions
- Healthy Participants
Interventions
AZD4144 Part ADrug
Part A: Participants will be administered a single oral dose on Day 1.
AZD4144 Part BDrug
Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
Placebo Part ADrug
Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
Placebo Part BDrug
Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Part A: From screening (Day -28 to Day -2) to Day 10; Part B: From screening (Day -28 to Day-2) to Day 20
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California
Research Site
Brooklyn, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.